Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

Endocrine-Related Cancer

Volumn 19, Issue 1, 2012, Pages

  Koumarianou, Anna ^a   Antoniou, Stavroula ^b   Kanakis, George ^b   Economopoulos, Nikolaos ^a   Rontogianni, Dimitra ^c   Ntavatzikos, Anastasios ^a   Tsavaris, Nikolaos ^b   Pectasides, Dimitrios ^a   Dimitriadis, George ^a   Kaltsas, Gregory ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CHROMOGRANIN A; DOCETAXEL; EVEROLIMUS; FLUOROURACIL; INTERFERON; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OCTREOTIDE; STREPTOZOCIN; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DACARBAZINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; BEDTIME DOSAGE; BLOOD VESSEL PERMEABILITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOTHELIUM CELL; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; AGED; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE;

EID: 84860338333     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0287     Document Type: Letter

References (15)

1. Bosman F, Carneiro F, Hruban R & Theise N Eds 2010 In WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press.
2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 45 228-247. (doi:10.1016/j.ejca.2008.10.026)
3. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M et al. 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clinical Cancer Research 13 2986-2991. (doi:10.1158/1078-0432.CCR-06-2053)
4. Grozinsky-Glasberg S, Shimon I, Korbonits M &Grossman AB 2008 Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocrine-Related Cancer 15 701-720. (doi:10.1677/ERC-07-0288)
5. Kulke M, Stuart K, Earle C, Bhargava P, Clark J, Enzinger P, Meyerhardt J, Attawia M, Lawrence C & Fuchs CA 2006a A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 24 4044. (doi:10.1200/JCO.2006.06.9823)
6. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS 2006b Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 401-406. (doi:10.1200/JCO.2005.03.6046)
7. Kulke M, Blaszkowsky L, Zhu A, Florio S, Regan E, Ryan D & Chan J 2010 Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). In 2010 ASCO Gastrointestinal Cancers Symposium. Abstract 223.
8. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ et al. 2011 Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of Clinical Oncology 29 934-943. (doi:10.1200/JCO.2010.33.2056)
9. Lam T, Hetherington JW, Greenman J, Little S &Maraveyas A 2007 Metronomic chemotherapy dosingschedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncologica 46 1169-1177. (doi:10.1080/02841860701373603)
10. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
11. Oberg K 2002 Management of neuroendocrine tumors. In ASCO Annual Meeting, pp 401-405.
12. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J & Kvols L 2011 First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 268-275. (doi:10.1002/cncr.25425)
13. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L et al. 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. British Journal of Cancer 88 1004-1011. (doi:10.1038/sj.bjc.6600827)
14. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C &Oberg K 2011 Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117 4617-4622. (doi:10.1002/cncr.26124)
15. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL & Ajani JA 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology 26 1316-1323. (doi:10.1200/JCO.2007.13.6374)